InspireMD, Inc. announced on October 15, 2024, the establishment of its new global headquarters in Miami, Florida. This move is intended to strategically position the company for the anticipated U.S. launch and commercialization of its CGuard Prime carotid stent system.
The Miami facility will serve as the base for building world-class commercial and operational teams and supporting infrastructure. This is a significant step in preparing for potential FDA approval of CGuard Prime, which was anticipated in the first half of 2025 at the time of this announcement.
Management stated that the new U.S.-based headquarters will be key to driving long-term growth and serving the U.S. market. The South Florida market provides access to talent and capacity, which is crucial as the company prepares for its U.S. launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.